Rockefeller Capital Management
AMED

Rockefeller Capital Management’s Amedisys AMED Stock Holding History

Rockefeller Capital Management’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-212
Closed -$21K – 3852
2022
Q2 		$21K Buy
212
+202
+2,020% +$25.8K ﹤0.01% 2704
2022
Q1 		$1K Sell
10
-39
-80% -$5.83K ﹤0.01% 3693
2021
Q4 		$7K Buy
49
+7
+17% +$1.13K ﹤0.01% 3126
2021
Q3 		$6K Buy
+42
New +$8.73K ﹤0.01% 3077
2021
Q1 		– Sell
-16
Closed -$4K – 3237
2020
Q4 		$4K Buy
+16
New +$4.1K ﹤0.01% 2460
2020
Q2 		– Sell
-21
Closed -$4K – 2568
2020
Q1 		$4K Hold
21
– – ﹤0.01% 1991
2019
Q4 		$4K Buy
+21
New +$3.12K ﹤0.01% 1809
2019
Q2 		– Sell
-130
Closed -$16K – 1646
2019
Q1 		$16K Buy
+130
New +$16.3K ﹤0.01% 1329

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rockefeller Capital Management's AMED Position: Q3 2022 in Review

Rockefeller Capital Management sold out of Amedisys (AMED) in Q3 2022, closing a stake of 212 shares — an estimated $21K sold.

Rockefeller Capital Management first reported a position in AMED in Q1 2019 and held it in 8 quarters. The position peaked at $21K in Q2 2022. 286 funds tracked by Wall St. Rank hold AMED as of Q3 2022.

  • Rockefeller Capital Management reported no remaining Amedisys position as of Q3 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 212 Amedisys shares in Q3 2022, an estimated $21K.
  • Rockefeller Capital Management first reported a position in Amedisys in Q1 2019 and held it in 8 quarters.
  • Rockefeller Capital Management's Amedisys position peaked at $21K in Q2 2022.
  • 286 funds tracked by Wall St. Rank held Amedisys as of Q3 2022.

Based on Rockefeller Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.